The first targeted cancer therapy was tamoxifen approved in 1970s. Tamoxifen binds to the estrogen receptor (ER), prevents estrogen from binding to ER, and therefore modulates ER activity. By interfering estrogen\'s ability to stimulate cancer cell growth, tamoxifen provides an effective treatment option for patients with ER-positive breast cancer. Following tamoxifen, multiple ER-targeting drugs were developed to include toremifene, fulvestrant, anastrozole, exemestance, and letrozole, forming the basis of endocrine therapies for ER-positive breast cancer.

In the past two decades, the discovery of oncogenes and tumor suppressor genes, and the completion of human genome sequencing fueled some major advances in our understanding of the molecular mechanisms leading to cancer. Subsequently, such newly emerging biological and genetic information rapidly prompted the introduction of a large number of new targeted cancer therapies.

Signaling pathways regulated by protein kinases are the frequent targets of somatic mutations, leading to many human cancers. Of the more than 100 dominant oncogenes known to date, many encode protein tyrosine kinases. Several mechanisms lead to aberrant function by protein tyrosine kinases and subsequent oncogenic transformation. These include (1) genomic rearrangements resulting in oncogenic fusion proteins that include the kinase catalytic domain and an unrelated protein that provides a constitutive activation/dimerization function, (2) gain-of-function mutations in the juxtamembrane or kinase domains or small deletions of regulatory regions, (3) overexpression with or without gene amplification, and (4) loss of the normal autoinhibitory and regulatory constraints of kinase activation. At this time, several tyrosine kinase inhibitors of variable target specificity have been approved by the Food and Drug Administration (FDA) for treatment of patients with a variety of cancers ([Table 1](#cjc-30-01-001-t01){ref-type="table"}).

Several receptor protein and cytoplasmic kinases are known to be mutated and/or overexpressed in human cancer. These include the epidermal growth factor receptor (EGFR; ErbB1), HER2/neu (ErbB2), insulin and insulin-like growth factor (IGF) receptors, fibroblast growth factor receptor-2 (FGFR-2), FGFR-4, Src, ABL, phosphoinositide 3-kinase (PI3K), MEK, RAF, among others. In many examples to be reviewed, inactivation of several of these kinases with exogenous inhibitors has resulted in an antitumor effect in preclinical models of cancer. And most importantly, some of these agents have shown promising clinical activity in patients with cancer and are in late development ([Table 2](#cjc-30-01-001-t02){ref-type="table"}). Several conditions are generally considered prior to the selection of a kinase as a therapeutic target against which drugs are developed. First, the kinase should be a "gain-of-function" Oncogene and/or causal to tumor development and tumor maintenance. It should be differentially expressed in tumor vs. non-tumor tissue and identifiable in cancer tissues. Although the kinase target may have a critical role in postnatal or adult physiology, it should provide a therapeutic window such that "tumor toxicity" occurs before prohibitive host tissue toxicity. Structure-function knowledge of the molecular target should be in hand in order to develop mechanism-based inhibitors. In general, kinase inhibitors have consisted of neutralizing antibodies, or low molecular weight ATP-mimetics and allosteric inhibitors.

###### US FDA approved targeted cancer therapies

  Brand name                  Compound name                        Company                       Target(s)                                        Indication\*
  ------------ ------------------------------------------- ----------------------- ------------------------------------- ---------------------------------------------------------------
  Xgeva                         Denosumab                           Amgen                       RANK ligand                                      Bone metastases
  Istodax                      Romidepsin                        Gloucester                        HDAC                                     Cutaneous T cell lymphoma
  Arzerra                      Ofatumumab                          Genmab                          CD-20                                  Chronic lymphocytic leukemia
  Votrient                      Pazopanib                            GSK             VGFR-1, -2 and -3, c-kit, PDGF-R                         Renal cell carcinoma
  Affinitor                    Everolimus                         Novartis                         mTOR                                       Renal cell carcinoma
  Tasigna                       Nilotinib                         Novartis                        BCR-ABL                 Philadelphia chromosome positive chronic myelogenous leukemia
  Torisel                     Temsirolimus                          Wyeth                          mTOR                                       Renal cell carcinoma
  Tykerb                        Lapatinib                      GlaxoSmithKline                  HER-2/EGFR                                        Breast cancer
  Sutent                    Sunitinib malate                       Pfizer                      VGFRs, PDGFR                              Gastrointestinal stromal tumor
  Sprycel                       Dasatinib                   Bristol-Myers Squibb               Src, BCR-ABL                                 Chronic myeloid leukemia
  Zolinza                      Vorinostat                           Merck                          HDAC                                     Cutaneous T-cell lymphoma
  Vectibix                     Panitumumab                          Amgen                          EGFR                                       Colorectal carcinoma
  Nexavar                  Sorafenib Tosylate                       Bayer           RAF, VEGFR-2 and -3, PDGFR-b, c-kit                       Renal cell carcinoma
  Tarceva                Erlotinib Hydrochloride                 OSI Pharms                        EGFR                                    Non-small cell lung cancer
  Avastin                      Bevacizumab                        Genentech                        VEGF                                         Colorectal cancer
  Erbitux                       Cetuximab                      ImClone Systems                     EGFR                                         Colorectal cancer
  Bexxar        Tositumomab and iodine ^131^I tositumomab    Corixa Corporation                    CD-20                                     Non-Hodgkin\'s lymphoma
  Velcade                      Bortezomib                     Millennium Pharms                 Proteasome                                      Multiple myeloma
  Iressa                        Gefitinib                        AstraZeneca                       EGFR                                    Non-small cell lung cancer
  Zevalin                 Ibritumomab tiuxetan                   IDEC Pharms                       CD-20                                 B-cell non-Hodgkin\'s lymphoma
  Campath                      Alemtuzumab                   Berlex Laboratories                   CD-52                              B-cell chronic lymphocytic leukaemia
  Gleevec                       Imatinib                          Novartis                 BCL-ABL, c-kit, PDGGR                            Chronic myeloid leukaemia
  Mylotarg                Gemtuzumab ozogamicin                 Wyeth/Pfizer                       CD-33                                     Acute myeloid leukaemia
  Ontak                    Denileukin diftitox                      Eisai                          IL-2                                     Cutaneous T-cell lymphoma
  Herceptin                    Trastuzumab                        Genentech                        HER2                                           Breast cancer
  Rituxan                       Rituximab                   Genentech/Biogen Idec                  CD-20                                     Non-Hodgkin\'s lymphoma

\*First indication approved by the United States Food and Drug Administration (US FDA).

HDAC, histone deacetylase; VGFR, vascular endothelial growth factor receptor; PDGF-R, platelet derived growth factor receptor; EGFR, epithelial growth factor receptor.

Challenges in Targeted Cancer Drug Development {#s2}
==============================================

Despite the advancement in targeted therapy, treatment of cancer still remains as a huge unmet medical need. Multiple factors, in addition to the complexity of cancer biology, contribute to this unsatisfactory state.

Lack of reliable preclinical models to predict anti-cancer drug efficacy {#s2a}
------------------------------------------------------------------------

Cancer development in human patients is a long multi-step process. The resulting malignant tumors are intimately intertwined with surrounding "normal" tissues. Such close tumor-host interactions are vitally important in determining the sensitivity of tumor cells to cancer treatments. However, such complex tumor context is not replicated either *in vitro* or *in vivo* in transgenic or xenograft models. Genetically engineering mouse tumor models provide a potentially promising alternate to assess preclinical cancer drug efficacy. But their true value has yet to be validated by clinical successes.

Inefficient clinical development {#s2b}
--------------------------------

Near 30% of the 98 000 clinical trials listed on Clinicaltrials.gov were related to cancer drugs. Such a large number not only reflects the huge unmet medical needs, but also stems from the low success rate of cancer medicine development. It is estimated that only 10% of the cancer drug candidates entering clinical stage ultimately gain market approval. New trial approaches are urgently needed especially for the development of targeted cancer therapies that will only benefit a subset of patients. Prospectively identifying sensitive or excluding resistant patient populations to achieve definitive clinical benefit led to successful development of several targeted therapies. Such successes include the use of HER2 fluorescent in situ hybridization (FISH) assay for selecting HER2-positive breast cancer patients receiving Herceptin treatment, EGFR mutation assay for selecting non-small cell lung cancer patients to be treated with gefitinib/erlotinib, and applying KRAS mutation assay to avoid exposing colorectal cancer patients with KRAS mutations to anti-EGFR mAbs. Recently, such biomarker-based prospective patient selection strategy was applied to Phase 1 studies to expedite clinical development of several new targeted agents. Overall response rates from 50% to near 80% were achieved in early phase trials of crizotinib (ALK inhibitor), as well as PLX-4032 (R7204) and GSK2118436 (bRAF V600E inhibitors). Such dramatic early efficacy data prompted sponsors launching Phase 3 registration trials based on Phase 1 and Phase 2 results ([Table 2](#cjc-30-01-001-t02){ref-type="table"}). For compounds lacking definitive biomarkers for identifying sensitive/resistant subpopulation, adaptive trial design to incorporate biomarker identification and validation into one single trial may represent an effective and efficient approach[@b1].

###### Selected targeted cancer therapies in late stage development

  Compound name                      Company                  Major indication                Target            Stage
  -------------------------- ----------------------- ---------------------------------- ------------------ ---------------
  Antibody                                                                                                 
   Ipilimumab                 Bristol-Myers Squibb                Melanoma                    CTLA4         BLA submitted
   Tremelimumab                 Pfizer/Debiopharm                 Melanoma                    CTLA4           Phase III
   Zalutumumab                       Genmab                 Head and neck cancer               EGFR           Phase III
   Pertuzumab                       Genentech                  Breast cancer                   HER2           Phase III
   Trastuzumab-DM1             Genentech/Immunogen             Breast cancer                   HER2           Phase III
  Small molecule                                                                                           
   Omacetaxlne                      ChemGenex         CML with T315I BCR-ABL mutation          MCL1         NDA submitted
   BSI-201                       Sanofi-Aventis        Triple-negative breast cancer          PARP1           Phase III
   ZD6474                          AstraZeneca        Failure of previous EGFR therapy         EGFR           Phase III
   IPI-504                          Infinity                        GIST                      HSP90           Phase III
   Ridaforolimus                   Ariad/Merck                    Sarcoma                      mTOR           Phase III
   XL184                            Exelixis              Medullary thyroid cancer       MET, VEGFR2, RET     Phase III
   PLX-4032 (R7204)              Roche/Plexxikon                  Melanoma                  BRAF V600E        Phase III
   GSK2118436                          GSK                        Melanoma                  BRAF V600E        Phase III
   Crizotinib (PF02341066)           Pfizer              Non-small cell lung cancer          EML4-ALK         Phase III
   ARQ197                     ArQule/Daiichi Sankyo      Non-small cell lung cancer           c-MET           Phase III

This table was modified from *Targeted cancer therapies* by Saurabh Aggarwal[@b3].

BLA, biologic license application; CML, chronic myeloid leukemia; CTLA4, cytotoxic T-lymphocyte protein 4; EGFR, epidermal growth factor receptor; GIST, gastrointestinal stromal tumor; HER2, human epidermal growth factor receptor 2 (also known as ERBB2); HSP90, heat-shock protein, 90 kDa; IGFR1, insulin-like growth factor receptor 1; MCL1, myeloid cell leukemia sequence 1; mTOR, mammalian target of rapamycin; NDA, new drug application; NSCLC, non-small cell lung cancer; PARP1, poly (ADP-ribose) polymerase 1.

Sources: company reports, ClinicalTrials.gov, American Society of Clinical Oncology, American Society of Hematology.

Limited single agent activity {#s2c}
-----------------------------

Most human tumors harbor numerous mutation events leading to activation of multiple signaling pathways. The redundancy in the signaling systems at the disposal of the cancer cells often render individual targeted agents inactive in treating most cancers. Even in rare exceptions, such as narrowly defined patient populations, single agent activities could be dramatic, but cancers still recur. Combinations of targeted agents represent a potentially effective approach to simultaneously inhibiting multiple pathways, suppressing feedback reactivation of compensatory signaling network, and therefore to prevent recurrence. The parallels between clinical development of combinations and understanding of cancer resistance will ultimately lead to personalized medicine, such as matching targeted therapy with cancer patients based on molecular events underlying their malignancies.

Opportunities for China {#s3}
=======================

The era of targeted cancer therapies brings unique opportunities to China. The already saturated clinical trial density in well established oncology trial regions such as North America and Western Europe poses an impassable challenge to accruing patients with proper molecular characteristics to match targeted agents. For example, nearly 7 000 patients need to be screened to identify the 5% patients with tumors harboring the EML4-ALK fusion event for the crizotinib Phase 3 trial of 320 patients. The success in contributing patients to the I-PASS trial is a beginning for China to play a more active role in global development of new anti-cancer agents[@b2]. In preparation for this new era, it is vital for investigators in China to master the knowledge in new cancer biology, pharmacokinetics, pharmacodynamics, innovative trial design of both early and late phases, as well as to establish core capabilities in molecular testing of tumor samples in real time fashion to support prospective patient selection.

In collaboration with US Chinese Anti-Cancer Association (USCACA), *Chinese Journal of Cancer* has organized a series of review articles to cover a broad spectrum of topics in targeted cancer therapies. These articles will analyze each major pathway or target class with an emphasis on mechanism of action, translational medicine, and clinical development. This series of reviews will provide a basis for our readers, especially clinical investigators, to develop a comprehensive appreciation of these targets and pathways in cancer as well as relevant targeted therapies being developed.

Authors would like to acknowledge Ms. Debbie Allison for her contribution and advice on the tables summarizing targeted agents.
